Meiragtx Holdings PLC 8-K filings

MeiraGTx reports strong Q2 2026 results, highlighted by the acquisition of botaretigene sparoparvovec, a $400 million strategic investment, and positive clinical data for AAV2-hAQP1.

MeiraGTx Holdings plc announced a significant strategic investment of up to $400 million from Oberland Capital, comprising $375 million in non-dilutive capital and $25 million in equity, to advance its late-stage gene therapy programs.

MeiraGTx Holdings plc announces results from its annual general meeting, with directors elected and auditor ratified.

MeiraGTx announced first quarter 2026 financial and operational results, highlighted by the acquisition of bota-vec for XLRP and positive three-year data for AAV2-hAQP1, alongside a $100 million financing.

MeiraGTx Holdings plc has completed the initial closing of a strategic collaboration with Hologen Limited to advance gene therapies for Parkinson's disease and obesity, along with a proprietary delivery device.

MeiraGTx Holdings plc has entered into an underwriting agreement to issue 11,111,111 ordinary shares at $9.00 per share to raise approximately $93.3 million in net proceeds.

MeiraGTx has reacquired the rights to its gene therapy product, bota-vec, from Janssen Pharmaceuticals for $25 million upfront.

MeiraGTx announced positive three-year durability data from its Phase 1 AQUAx study of AAV-hAQP1 for radiation-induced xerostomia.

MeiraGTx announced FDA Breakthrough Therapy Designation for its RIX treatment, extended its debt maturity, and reported full-year 2025 financial results.

MeiraGTx Holdings plc announced an $18.19 million share repurchase from Perceptive Life Sciences Master Fund, Ltd., a significant shareholder, as part of Perceptive's year-end tax optimization.

MeiraGTx announced Q3 2025 financial results and significant strategic collaborations with Eli Lilly and Hologen AI, bolstering its gene therapy pipeline and financial runway.

MeiraGTx announced a strategic collaboration and license agreement with Eli Lilly and Company for the research, development, and commercialization of genetic medicines in ophthalmology.

MeiraGTx reported Q2 2025 financial results, highlighted significant regulatory progress across its late-stage gene therapy pipeline, and announced the initial funding receipt from its strategic collaboration with Hologen.

MeiraGTx Holdings plc announced it has received all necessary UK foreign direct investment clearances for its previously disclosed transactions with Hologen Limited, with closing expected in July 2025.

MeiraGTx Holdings plc announced the results of its annual general meeting held on June 12, 2025, where shareholders elected a Class I director and ratified the appointment of Ernst & Young LLP as the independent auditor.

MeiraGTx reports positive regulatory interactions, a strategic collaboration with Hologen AI for $200 million upfront, and progress across its clinical programs in Q1 2025.

MeiraGTx's AAV-GAD receives Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating Parkinson's disease, potentially accelerating its development and review.

MeiraGTx Holdings plc subsidiary, MeiraGTx, LLC, has entered into a new lease agreement for additional laboratory and office space in New York City and will terminate its existing sublease at the same location.

MeiraGTx partners with Hologen AI in a deal worth up to $430 million to advance its Parkinson's disease program and manufacturing capabilities.

MeiraGTx has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its AAV2-hAQP1 therapy targeting radiation-induced xerostomia.

MeiraGTx reported positive clinical data for its Parkinson's disease treatment, secured three Rare Pediatric Disease Designations, and advanced its AIPL1 program towards potential regulatory approval.

MeiraGTx reports positive results from a clinical bridging study of AAV-GAD gene therapy for Parkinson's disease, showing significant improvements in motor function and quality of life.

MeiraGTx Holdings successfully completed a public offering of 12.5 million ordinary shares, raising approximately $48.3 million in net proceeds to fund operations into the second quarter of 2026.

MeiraGTx has announced a $50 million share offering led by Sanofi, along with its second quarter 2024 financial and operational results, highlighting positive clinical data and regulatory advancements.

MeiraGTx Holdings plc held its annual general meeting on June 6, 2024, where shareholders elected three Class III directors and approved other key proposals.

MeiraGTx announced positive clinical data from its Phase 1 AQUAx study and a $50 million milestone payment, alongside its first quarter 2024 financial results.

MeiraGTx Holdings plc filed an amendment to its previous 8-K report to disclose the committee appointments of new board member, Dr. Debra Yu.

MeiraGTx announced its full year 2023 financial and operational results, highlighting progress in clinical programs, strategic partnerships, and manufacturing capabilities.

MeiraGTx has received a $50 million milestone payment from Janssen Pharmaceuticals following the initiation of an extension study for its Phase 3 clinical trial of botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa (XLRP).